NCT06510114View on ClinicalTrials.gov

A Randomized Clinical Trial of Intravenous Methylprednisolone With 2 Protocols in Patients With Graves Orbitopathy

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Graves Ophthalmopathy
Interventions
DRUG

methylprednisolone(daily scheme)

0.5 g methylprednisolone i.v. daily for 5 consecutive days, followed by oral prednisone for 6 months. Oral prednisone started at 40 mg/day for 4 weeks and then the dose was tapered by 5 mg/day every 2-4 weeks.

DRUG

methylprednisolone(weekly scheme)

0.5 g methylprednisolone i.v. weekly for 6 weeks and then the dose was tapered by 0.25 g/week over the following 6 weeks.

All Listed Sponsors
lead

Third Affiliated Hospital, Sun Yat-Sen University

OTHER